← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Teduglutide

FDA approved · Rx

GLP-2 analog

Also known as: Gattex, revestive, ALX 0600, ALX-0600, Gattex Kit, Gly(2)-GLP-2, teduglutidum

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 50 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Teduglutide is a synthetic version of glucagon-like peptide-2 (GLP-2), a natural gut hormone, with one amino acid changed so it lasts longer in the body. It is thought to act on GLP-2 receptors in the intestine, promoting growth of the intestinal lining and improving the absorption of fluids and nutrients.

What the evidence shows

Automatic summaryHuman trials

Teduglutide is FDA-approved (as Gattex) for adults and children with short bowel syndrome who depend on parenteral support, supported by about 50 registered human trials up to Phase 4. Use outside this approved indication is not established.

Key facts

Molecular formula
C164H252N44O55S
Molecular weight
3752.1 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

50registered studies
Phase 4most advanced phase
42completed (sample)
2recruiting (sample)

Teduglutide in Short Bowel Syndrome Patients

CompletedNCT04857801

A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants

Phase 1CompletedNCT04465396

Registry for Participants With Short Bowel Syndrome

Active Not RecruitingNCT01990040

A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older

Phase 3CompletedNCT05027308

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

365papers referencing Teduglutide

Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.

Gut2005

Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.

Gastroenterology2012

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.

Gut2011

Intestinal adaptation following resection.

JPEN J Parenter Enteral Nutr2014

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.